Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro

Biomaterials

Volumn 78, Issue , 2016, Pages 1-10

  Leite, Sofia B ^a   Roosens, Tiffany ^a   El Taghdouini, Adil ^a   Mannaerts, Inge ^a   Smout, Ayla J ^a   Najimi, Mustapha ^b   Sokal, Etienne ^b   Noor, Fozia ^c   Chesne, Christophe ^d   van Grunsven, Leo A ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c SAARLAND UNIVERSITY   (Germany)

^d Biopredic International   (France)

Author keywords

Allyl alcohol; APAP; DILI; HepaRG; Hepatic stellate cell; Hepatocyte; In vitro; Liver fibrosis; Methotrexate; Organoid

Indexed keywords

GENE EXPRESSION; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ALLYL ALCOHOLS; APAP; DILI; HEPARG; HEPATIC STELLATE CELLS; HEPATOCYTES; IN-VITRO; LIVER FIBROSIS; METHOTREXATE; ORGANOID;

CHEMICAL ACTIVATION;

BIOLOGICAL MODEL; CELL LINE; CHEMICALLY INDUCED; HUMAN; LIVER; LIVER CIRRHOSIS; PATHOLOGY;

CELL LINE; HUMANS; LIVER; LIVER CIRRHOSIS; MODELS, BIOLOGICAL;

EID: 84949961772     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.11.026     Document Type: Article

References (39)

1. Mederacke I., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 2013, 4:2823.
2. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
3. Olsen A.L., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G110-G118.
4. Coll M., et al. Integrative miRNA and gene expression profiling analysis of human quiescent hepatic stellate cells. Sci. Rep. 2015, 5:11549.
5. Dusabineza A.C., et al. Hepatic stellate cells improve engraftment of human primary hepatocytes: a pre-clinical transplantation study in animal model. Cell Transpl. 2015.
6. Thoen L.F., et al. A role for autophagy during hepatic stellate cell activation. J. Hepatol. 2011, 55:1353-1360.
7. El Taghdouini A., et al. Genome-wide analysis of DNA methylation and gene expression patterns in purified, uncultured human liver cells and activated hepatic stellate cells. Oncotarget. 2015, 6:26729-26745.
8. Klein S., Mueller D., Schevchenko V., Noor F. Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study. J. Appl. Toxicol. 2014, 34:1078-1086.
9. Lubberstedt M., et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 2011, 63:59-68.
10. Leite S.B., et al. Three-dimensional HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 2012, 130:106-116.
11. Gunness P., et al. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci. 2013, 133:67-78.
12. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
13. Folkman J., Hochberg M. Self-regulation of growth in three dimensions. J. Exp. Med. 1973, 138:745-753.
14. Antherieu S., Rogue A., Fromenty B., Guillouzo A., Robin M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011, 53:1895-1905.
15. Bogman K., Erne-Brand F., Alsenz J., Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. 2003, 92:1250-1261.
16. Antoine D.J., et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013, 58:777-787.
17. Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 1996, 271:12063-12067.
18. Nakagawa H., et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 2008, 135:1311-1321.
19. Herrmann J., Haas U., Gressner A.M., Weiskirchen R. TGF-beta up-regulates serum response factor in activated hepatic stellate cells. Biochim. Biophys. Acta 2007, 1772:1250-1257.
20. Marques P.E., et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology 2012, 56:1971-1982.
21. Pradere J.-P., et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013, 58:1461-1473.
22. Aoyama T., Paik Y.H., Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, 2010:1-8.
23. Mannaerts I., et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 2010, 51:603-614.
24. Kisseleva T., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9448-9453.
25. Chen C., Krausz K.W., Idle J.R., Gonzalez F.J. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 2008, 283:4543-4559.
26. Prill S., et al. Real-time monitoring of oxygen uptake in hepatic bioreactor shows CYP450-independent mitochondrial toxicity of acetaminophen and amiodarone. Arch. Toxicol. 2015.
27. Mitchell C., et al. Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. Am. J. Pathol. 2009, 175:1929-1937.
28. Jung S.A., et al. Experimental model of hepatic fibrosis following repeated periportal necrosis induced by allylalcohol. Scand. J. Gastroenterol. 2000, 35:969-975.
29. Lindsay K., et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatol. Oxf. 2009, 48:569-572.
30. Pomponio G., et al. In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments. Toxicol. In Vitro 2014.
31. Covaci O.I., Bucur B., Radu G.L. Acrolein detection based on alcohol dehydrogenase inhibition. Int. J. Environ. Anal. Chem. 2013, 93:325-334.
32. Auerbach S.S., Mahler J., Travlos G.S., Irwin R.D. A comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein. Toxicology 2008, 253:79-88.
33. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4:489-499.
34. Vinken M. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 2013, 312:158-165.
35. Leite S.B., et al. Merging bioreactor technology with 3D hepatocyte-fibroblast culturing approaches: improved in vitro models for toxicological applications. Toxicol In Vitro 2011, 25:825-832.
36. Nambotin S.B., Tomimaru Y., Merle P., Wands J.R., Kim M. Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis 2012, 1:e31.
37. Watelet J., et al. Toxicity of chronic paracetamol ingestion. Aliment. Pharmacol. Ther. 2007, 26:1543-1544. author reply 1545-1546.
38. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 2013, 5. 167sr161.
39. Henderson N.C., et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 2013, 19:1617-1624.